Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070285
Filing Date
2025-05-13
Accepted
2025-05-13 16:03:52
Documents
59
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fate-20250331.htm   iXBRL 10-Q 2392918
2 EX-31.1 fate-ex31_1.htm EX-31.1 12731
3 EX-32.1 fate-ex32_1.htm EX-32.1 8507
  Complete submission text file 0000950170-25-070285.txt   10373058

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fate-20250331.xsd EX-101.SCH 1286630
62 EXTRACTED XBRL INSTANCE DOCUMENT fate-20250331_htm.xml XML 2278295
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36076 | Film No.: 25939892
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)